Newcastle disease virus recombinant vaccine strain inserted with HA protein of H7N9

• Main Authors: HU XIUXIANG, SUN HUALU, ZHI YONG, YU ZEKUN, SUN NANA, LI SIFEI, LIU YANG, YAN RUIJUAN, LI MINGYI, LUAN ZHIFANG, LI CHAOYANG, SHAN XUEQIANG
• Format: Patent
• Language: Chinese; English
• Published: 08.03.2019
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES USING MICROORGANISMS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The invention aims to provide a Newcastle disease virus recombinant vaccine strain inserted with an HA protein of H7N9. The problems that a recombinant virus for expressing the HA protein of the avianinfluenza virus H7N9 is low in expression efficiency, the induced antibody level is not high and the immunogenicity is not ideal are solved by optimizing the sequences of encoding genes of the HA protein of the avian influenza virus H7N9. After an animal is immunized by the prepared low virulent strain, a very good protecting effect can be provided for the current pandemic gene VII Newcastle disease virus, and meanwhile, prevention and control can be provided for the attack of the avian influenza virus H9N2. 本发明的目的是提供种插入H7N9的HA蛋白的新城疫病毒重组疫苗株,本发明通过对H7N9病毒HA蛋白的编码基因进行序列优化，解决了表达禽流感H7N9病毒HA蛋白的重组毒表达效率较低，诱导的抗体水平不高，免疫原性不理想的问题。制备的弱毒株免疫动物后均可以对当前流行的基因VII新城疫病毒提供良好的保护作用，同时可以提供对H9N2禽流感病毒侵害的防控。